J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horowitz, B.
Right arrow Articles by Ito, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horowitz, B.
Right arrow Articles by Ito, S
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Evolving pathogens in vulvovaginal candidiasis: implications for patient care

BJ Horowitz, D Giaquinta, and S Ito

Over the past two decades, an increasing trend in the number of vaginal infections attributable to yeasts other than Candida albicans has emerged. Of these non-albicans species, C. tropicalis and C. glabrata appear to be the most important. The change in incidence pattern of yeast vaginitis can be expected to impact greatly on the treatment of this condition, because many currently used drug therapies (e.g., imidazoles) for C. albicans vaginitis do not adequately eradicate non-albicans species. A possible explanation for the recent increased selection of these species may be the shortened antifungal therapies that have been introduced during the past decade. These 1- to 3-day regimens with the older imidazoles may suppress C. albicans, but create an imbalance of flora that facilitate an overgrowth of non-albicans species. The recognition of yeast speciation and the need for use of a broad-spectrum antifungal preparation that covers these organisms is now apparent.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Fam PractHome page
S. Sihvo, R. Ahonen, H. Mikander, and E. Hemminki
Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns
Fam. Pract., April 1, 2000; 17(2): 145 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
M. S. Lipsky and T. Waters
The "Prescription-to-OTC Switch" Movement: Its Effects on Antifungal Vaginitis Preparations
Arch Fam Med, July 1, 1999; 8(4): 297 - 300.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. D. Sobel
Vaginitis
N. Engl. J. Med., December 25, 1997; 337(26): 1896 - 1903.
[Full Text] [PDF]

Home page
 Arch Fam MedHome page
J. K. Kirk
Pharmacotherapy Price Comparison
Arch Fam Med, September 1, 1995; 4(9): 811 - 811.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Clinical Pharmacology